A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
Alugubelli YR, Geng ZZ, Yang KS, Shaabani N, Khatua K, Ma XR, Vatansever EC, Cho CC, Ma Y, Xiao J, Blankenship LR, Yu G, Sankaran B, Li P, Allen R, Ji H, Xu S, Liu WR.
Alugubelli YR, et al.
Eur J Med Chem. 2022 Oct 5;240:114596. doi: 10.1016/j.ejmech.2022.114596. Epub 2022 Jul 8.
Eur J Med Chem. 2022.
PMID: 35839690
Free PMC article.
A unique observation was made with an inhibitor that contains a P4 N-terminal isovaleramide. In its M(Pro) complex structure, the P4 N-terminal isovaleramide is tucked deep in a small pocket of M(Pro) that originally recognizes a P4 alanine side chain in a substrate …
A unique observation was made with an inhibitor that contains a P4 N-terminal isovaleramide. In its M(Pro) complex structure, the P4 …